AstraZeneca   4Q Revenues: $7.3 billion (-16%) 4Q Earnings: $1.5 billion (-8%) FY Revenues: $28 billion (-17%) FY Earnings: $6.3 billion (-18%) Comments: U.S. revenues were down 23% in the quarter as a result of the loss of exclusivity for Seroquel IR. The negative impact of U.S. healthcare reform on revenue and costs in the quarter was approximately $250 million. Revenue in the Rest of World was down 9% and revenue in Western Europe was down 16%. Loss of exclusivity on Seroquel IR, Atacand,...